Several brokerages have updated their recommendations and price targets on shares of MEDNAX (NYSE: MD) in the last few weeks:

  • 2/12/2018 – MEDNAX had its price target raised by analysts at BMO Capital Markets from $46.00 to $58.00. They now have a “market perform” rating on the stock.
  • 2/12/2018 – MEDNAX had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $55.00. They now have a “neutral” rating on the stock.
  • 2/9/2018 – MEDNAX was given a new $53.00 price target on by analysts at Mizuho. They now have a “neutral” rating on the stock.
  • 2/9/2018 – MEDNAX had its price target raised by analysts at Robert W. Baird from $48.00 to $54.00. They now have a “neutral” rating on the stock.
  • 2/8/2018 – MEDNAX was given a new $62.00 price target on by analysts at Stephens. They now have a “buy” rating on the stock.
  • 2/6/2018 – MEDNAX was given a new $50.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.
  • 1/24/2018 – MEDNAX was given a new $49.00 price target on by analysts at Mizuho. They now have a “hold” rating on the stock.
  • 1/24/2018 – MEDNAX had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $56.00 price target on the stock.
  • 1/23/2018 – MEDNAX was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $60.00 price target on the stock. According to Zacks, “Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. “
  • 12/21/2017 – MEDNAX was given a new $55.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “hold” rating on the stock.

MEDNAX Inc (NYSE MD) opened at $53.94 on Monday. The firm has a market cap of $5,051.76, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 1.47 and a beta of 0.31. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.37 and a current ratio of 1.43. MEDNAX Inc has a 12-month low of $40.56 and a 12-month high of $72.13.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.04. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. During the same period in the previous year, the company posted $1.00 earnings per share. MEDNAX’s revenue was up 9.6% compared to the same quarter last year. equities research analysts predict that MEDNAX Inc will post 3.67 EPS for the current year.

In other news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.